Research progress of therapeutic drugs for relapsed/refractory multiple myeloma
Multiple myeloma(MM)is a common blood system tumor characterized by the accumulation of clonal plasma cells in the bone marrow.Most MM will eventually evolve into recurrent/refractory multiple myeloma(RRMM),but for mul-tidrug resistant RRMM patients,the efficacy of conventional cytotoxic drugs and targeted drugs are not ideal.In recent years,with the improvement of medical level and the deepening of clinical research,the clinical trial data of the new generation of original targeted drugs and new anti-MM drugs are continuously accumulated and updated,and they have shown good safety and encouraging activity,which can better relieve the symptoms of patients and prolong the survival time of patients.This review aims to collect,analyze and summarize the clinical data of iterative anti-MM targeted drugs and new anti-MM drugs,in order to understand the current development trend and provide reference for the formulation of treatment plans for RRMM patients.
Recurrent/refractory multiple myelomaTargeted drugsCombined therapyClinical study
国家科技期刊平台
NSTL
万方数据
维普
